PcG蛋白与血液肿瘤及靶向治疗的相关性研究进展  

Research Progress in Correlation between PcG Protein and Hematological Malignancies and Targeted Therapies

作　　者：卞育婕 初雅婧 袁卫平 BIAN Yujie;CHU Yajing;YUAN Weiping(State Key Laboratory of Experimental Hematology,Institute of Hematology&Blood Diseases Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Tianjin 300020,China)

机构地区：[1]中国医学科学院北京协和医学院血液病医院(血液学研究所)实验血液学国家重点实验室,天津300020

出　　处：《医学综述》2020年第9期1665-1672,1678,共9页Medical Recapitulate

基　　金：国家自然科学基金(81770105,81629001);天津市自然科学基金(17JCQNJC09800);天津市科技计划项目(18ZXDBSY00070)。

摘　　要：血液肿瘤是原发于造血器官并主要累及造血系统的高度异质性恶性疾病,细胞遗传学和表观遗传学的改变共同导致了血液肿瘤的发生。与细胞遗传学改变不同,表观遗传学改变具有可逆性。组蛋白修饰是一种重要的表观遗传修饰方式,PcG蛋白进行组蛋白修饰以调控细胞增殖、分化、细胞周期等细胞内基本生命活动。PcG蛋白可调控造血干细胞的功能,异常表达的PcG蛋白致使造血干细胞功能无法维持造血稳态,进而导致多种血液肿瘤的发生。因此,研究表观遗传学的变异可以为血液肿瘤提供重要的分子标志和潜在的治疗靶点。Hematological malignancies are highly heterogeneous diseases originating from the hematopoietic organs and mainly involving the hematopoietic system. The combined cytogenetics and epigenetics changes lead to hematological malignancies. Unlike cytogenetic variations,epigenetic changes are reversible. As an important regulator in epigenetic modification,Pc G protein regulates cell proliferation,differentiation and cell cycle by histone modification. Pc G protein can regulate the function of hematopoietic stem cells. Abnormally expressed Pc G protein fails maintain hematopoietic homeostasis,leading to various hematological malignacies. Thus,studies on epigenetic variation can provide important molecular markers and potential therapeutic targets for the treatment of hematological malignancies.

关 键 词：血液肿瘤 PCG蛋白 造血干细胞 靶向治疗 

分 类 号：R730.2[医药卫生—肿瘤]